Taken together with our present finding, loss of SET7/9 expression may promote the tumor progression through absences of H3K4me1 and methylation of non-histones in carcinogenesis, and hence restoration of SET7/9 expression could contribute to new therapeutic strategies for GCs. This evidence concerns the gene SETD7 and neoplasm.